First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma (Q35111925)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma (English)

1 reference

Europe PubMed Central

6 August 2017

1 reference

ChEBI release 2020-05-28

18

object named as

Jose Baselga

1 reference

Europe PubMed Central

6 August 2017

object named as

Irene Braña

7

1 reference

ORCID Public Data File 2021

N Sokalingum Pillay

11

object named as

N Sokalingum Pillay

1 reference

Europe PubMed Central

6 August 2017

10

object named as

Ann L Cleverly

1 reference

Europe PubMed Central

6 August 2017

author name string

Jordi Rodon

1

1 reference

Europe PubMed Central

6 August 2017

Michael A Carducci

2

1 reference

Europe PubMed Central

6 August 2017

Juan M Sepulveda-Sánchez

3

1 reference

Europe PubMed Central

6 August 2017

Analia Azaro

4

1 reference

Europe PubMed Central

6 August 2017

Emiliano Calvo

5

1 reference

Europe PubMed Central

6 August 2017

Joan Seoane

6

1 reference

Europe PubMed Central

6 August 2017

Elisabet Sicart

8

1 reference

Europe PubMed Central

6 August 2017

Ivelina Gueorguieva

9

1 reference

Europe PubMed Central

6 August 2017

Durisala Desaiah

12

1 reference

Europe PubMed Central

6 August 2017

Shawn T Estrem

13

1 reference

Europe PubMed Central

6 August 2017

Luis Paz-Ares

14

1 reference

Europe PubMed Central

6 August 2017

Matthias Holdhoff

15

1 reference

Europe PubMed Central

6 August 2017

Jaishri Blakeley

16

1 reference

Europe PubMed Central

6 August 2017

Michael M Lahn

17

1 reference

Europe PubMed Central

6 August 2017

language of work or name

0 references

publication date

25 November 2014

1 reference

Europe PubMed Central

6 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

6 August 2017

21

1 reference

Europe PubMed Central

6 August 2017

3

1 reference

Europe PubMed Central

6 August 2017

553-560

1 reference

Europe PubMed Central

6 August 2017

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Tumor-promoting functions of transforming growth factor-β in progression of cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

TGF-beta signaling in tumor suppression and cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

TGFbeta signaling in growth control, cancer, and heritable disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

9 July 2018

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

Induction of heart valve lesions by small-molecule ALK5 inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4337847

27 September 2018

Identifiers

10.1158/1078-0432.CCR-14-1380

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35111925&oldid=2117041022"